12 July 2024
CVS Group plc
("CVS" or the "Company")
Block Listing Interim Review
CVS, one of the UK's leading providers of integrated veterinary services, makes the following notification pursuant to Schedule Six of the AIM Rules for Companies regarding its existing block listing arrangements. References to securities are to the Company's ordinary shares of 0.2 pence each ("Ordinary Shares").
Name of the company: | CVS Group plc
| |||
Name of relevant scheme: | 1. CVS Group SAYE Plan; and 2. CVS Long Term Incentive Plan*
| |||
Period of return: | From: | 12 January 2024 | To: | 12 July 2024 |
Balance of unallotted securities under scheme(s) from previous return: | 1. 392,455 2. 68,393 | |||
Plus: The amount by which the block scheme(s) has been increased since the date of the last return (if any increase has been applied for): | 1. Nil 2. Nil | |||
Less: Number of securities issued / allotted under scheme(s) during period: | 1. 48,148 2. Nil | |||
Equals: Balance under scheme(s) not yet issued / allotted at end of period: | 1. 344,307 2. 68,393 | |||
Number and class of securities originally listed and the date of admission: | 1. 350,000 Ordinary Shares admitted on 30 December 2021 2. 120,000 Ordinary Shares admitted on 15 May 2023 | |||
*Previously referred to as Long Term Incentive Plan 2017
Contacts:
CVS Group plc via Camarco
Richard Fairman, CEO
Scott Morrison, Company Secretary
Peel Hunt LLP (Nominated Adviser & Broker) +44 (0)20 7418 8900
Christopher Golden / James Steele / Andrew Clark / Lalit Bose
Berenberg (Joint Broker) +44 (0)20 3207 7800
Toby Flaux / Ben Wright / Ciaran Walsh / Milo Bonser
Camarco (Financial PR)
Geoffrey Pelham-Lane +44 (0)7733 124 226
Ginny Pulbrook +44 (0)7961 315 138
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.